All In Biotech

Drug Trial Radar · NCT04841577

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

A Phase 3, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU-QIV Vaccine in Adults Aged 60 Years and Above

Last checked: Nov 20, 2026Latest source record: Sep 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 976 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

976

Actual

Start

Apr 27, 2021

Primary completion

Sep 22, 2021

Study completion Feb 8, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the seasonal quadrivalent influenza vaccine (FLU-QIV) in adults aged 60 years and above compared to separate administration of the vaccines.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA investigational vaccineBiological

    RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

  • FLU-QIVBiological

    FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RSV-A Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMTs)Time frame: At 1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
  2. Hemagglutinin Inhibition (HI) Antibody Titers for Each of the FLU Vaccine Strains Expressed as Group GMTsTime frame: 1 month after the FLU vaccine dose (at Day 31)

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Auckland, New Zealand

  • GSK Investigational Site

    Auckland, New Zealand

  • GSK Investigational Site

    Christchurch, New Zealand

  • GSK Investigational Site

    Havelock North, New Zealand

  • GSK Investigational Site

    Paraparaumu, New Zealand

  • GSK Investigational Site

    Tauranga, New Zealand

  • GSK Investigational Site

    Wellington, New Zealand

  • GSK Investigational Site

    Panama City, Panama

  • GSK Investigational Site

    Panama City, Panama

  • GSK Investigational Site

    Panama City, Panama

  • GSK Investigational Site

    Panama City, Panama

  • GSK Investigational Site

    Panama City, Panama

  • GSK Investigational Site

    Boksburg, Gauteng, South Africa

  • GSK Investigational Site

    Middelburg, Mpumalanga, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.